NCT04521296View on ClinicalTrials.gov

Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

432

Participants

Timeline

Start Date

September 11, 2020

Primary Completion Date

September 14, 2021

Study Completion Date

March 18, 2022

Conditions
Mild to Moderate COVID-19
Interventions
OTHER

Part 1

\- DWJ1248 600mg PO (100mg 2 tab, TID)

OTHER

Part 2

\- DWJ1248 600mg PO (200mg 1 tab, TID)

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY